Melissa Leichter: My Team Used AI to Pinpoint Likely Undiagnosed Patients with Glanzmann’s Thrombasthenia
Melissa Leichter, Rare Disease Executive at Novo Nordisk, shared on LinkedIn:
”I’ve had a number of conversations recently with commercial colleagues about AI, and we’re all struck by how dramatically it can change patient outcomes.
For people living with an undiagnosed disease, getting clarity on their condition can stretch on for years.
Their life quickly becomes a marathon of misdiagnoses, trying to find the right specialists, waiting for openings on those doctors’ schedules, insurance delays, and other hurdles to clear.
AI, with its ability to parse vast amounts of data and surface patterns that otherwise would remain hidden, can significantly shorten that painful journey.
I’ve seen this in action in a rare disease context.
My team used AI to pinpoint likely undiagnosed patients with Glanzmann’s Thrombasthenia, an ultra-rare platelet disorder, by analyzing a blend of diagnostic codes, medication usage, and procedure records.
We were able to illuminate complex data that could trigger an earlier intervention.
We need to do more to unleash AI as a tool in patient diagnosis, and the biggest obstacle to that is data fragmentation.
Health record systems rarely talk to each other, even within a single institution, resulting in disconnected pockets of patient information.
Moving forward, it’s essential that we invest in data connectivity and unified patient journeys.
Only then can machine learning help us shrink the timeline between debilitating symptoms and life-changing diagnoses at scale — and improve the lives of countless patients.”
Read the full article here.
Article: How Sanford Health Embeds AI into Its EHR to Catch Disease Earlier and Personalize Care
Authors: Katie Adams
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:23Joseph R. Shaw: Thrombin Generation and the Pharmacodynamics of Oral Anticoagulants